#ASH17: Ve­rastem's Ab­b­Vie castoff is head­ed for the FDA — even af­ter miss­ing over­all sur­vival goal

When Ve­rastem $VSTM CEO Robert For­rester high­light­ed the pos­i­tive end­point from the piv­otal study of du­velis­ib a few months ago, he didn’t want to talk about the sec­ondary da­ta points. That, he said, was be­ing saved for a fu­ture sci­en­tif­ic con­fer­ence.

And to­day at ASH you can see the added da­ta isn’t some­thing you’d want to dis­cuss much.

The drug — which hit sta­tis­ti­cal sig­nif­i­cance on pro­gres­sion-free sur­vival — flunked the key over­all sur­vival sec­ondary, fail­ing to do any bet­ter than Arz­er­ra (ofa­tu­mum­ab) in ex­tend­ing the lives of pa­tients with re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia/small lym­pho­cyt­ic lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER